Project Grant R00CA297022
Award Date 9/16/25
Completion Date 8/31/28
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This $284,590 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to identify gut microbial and metabolomic biomarkers associated with ultra-processed food consumption and colorectal cancer risk. The award will fund a two-part study led by researchers at the Harvard T.H. Chan School of Public Health. The K99 research will characterize gut microbial and metabolomic signatures of ultra-processed food intake and their links to...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...
- The federal Project Grant award of $397,772 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research program) to Harvard T.H. Chan School of Public Health. The grant will fund the development of computational methods for profiling the cancer virome and analyzing microbial strain genetics from shotgun metagenomes and metatranscriptomes. This research aims to address key knowledge gaps in understanding the role of viruses and microbial strain variations...
- This $192,888 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a research project at the University of Virginia (UVA) to investigate the use of normal colon organoids for identifying causal genetic variants associated with colorectal cancer risk. The key objectives of the project are to: 1) test the hypothesis that colorectal cancer GWAS genes are cell type-specific, and 2) determine the role of these genes within colon epithelial...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- This federal Project Grant award of $400,890.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The goal is to provide a strategic roadmap and personalized workflow to enhance immunotherapeutic effects on non-responsive...
- The federal Project Grant award of $697,763 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The University of Texas MD Anderson Cancer Center to decipher the critical determinants of how the Fusobacterium nucleatum (FN) bacteria colonizes the colorectal cancer (CRC) tumor microenvironment and contributes to disease progression. The project aims to gain mechanistic insights into how this oral bacteria homes to and persists within the CRC tumor, as...
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...